A separate analysis of older (≥60) AML patients was able to show dramatically different outcomes for patients treated with traditional 7 + 3 induction chemotherapy, when the mutational status of seven genes (NPM1, ASXL1, DNMT3A, FLT3‐ITD, NRAS, TP53, KRAS) was added to traditional cytogenetics to create the ALFA decision model, which was validated among a three large (n = 830) cohorts [89]. The gene discussed is TP53; the disease is acute myeloid leukemia.